GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

by barry-jtcir | May 13, 2024 | Press Releases

Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 Ongoing progress of Investigational New Drug (IND) enabling studies in...

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

by barry-jtcir | Apr 29, 2024 | Press Releases

LA JOLLA, CA, April 29, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

by barry-jtcir | Apr 25, 2024 | Press Releases

Live webcast on Wednesday, May 1st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators...

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

by barry-jtcir | Apr 16, 2024 | Press Releases

Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation Continued advancement of an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune...

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

by barry-jtcir | Apr 8, 2024 | Press Releases

LA JOLLA, CA, April 08, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...